Research programme: skin diseases therapeutics - Quark Pharmaceuticals
Alternative Names: QP-AL1; QP-AL2Latest Information Update: 28 Feb 2024
At a glance
- Originator Quark Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alopecia
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Alopecia(Chemotherapy-induced) in USA
- 28 Jan 2024 No recent reports of development identified for research development in Alopecia in USA
- 30 Jan 2020 Early Research for Alopecia is ongoing USA